David Martin, MD
Nephrology · Euless, TXNPI 1093774127
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,340 of the $1,826 with a category attached, or 73.4%. Otsuka America Pharmaceutical, Inc. accounts for 83.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $1,340 and has fallen 95.3% since, to $63 in 2025.
Across 8 payments — averaging $228.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Vifor Pharma, Inc.$200
- Novartis$63
- Mindray DS USA, Inc.$19
- Baxter Healthcare$13
What the payments were for
- Consulting fees$1,34073%
- Speaking & faculty fees$20011%
- Food & beverage$955%
- Education$19110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $1,531 |
| Vifor Pharma, Inc. | 1 | $200 |
| Novartis | 2 | $63 |
| Mindray DS USA, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,826 in reported general payments places this provider in the 55th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 11 | $32,731 |
| FarxigaDapagliflozin Propanediol | 20 | $25,721 |
| VeltassaPatiromer Calcium Sorbitex | 23 | $25,015 |
| Sevelamer Carbonate | 61 | $13,113 |
| Calcium Acetate | 36 | $3,058 |
| Olmesartan Medoxomil | 41 | $1,481 |
| Losartan Potassium | 130 | $1,388 |
| Torsemide | 58 | $1,268 |
| Furosemide | 162 | $1,043 |
| Midodrine Hcl | 35 | $1,005 |
| Potassium Chloride | 40 | $769 |
| Carvedilol | 86 | $738 |
| Hydralazine Hcl | 56 | $725 |
| Chlorthalidone | 41 | $722 |
| Amlodipine Besylate | 138 | $674 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Euless
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.